HEAL Initiative: Understanding Polysubstance Use and Improving Service Delivery to Address Polysubstance Use (R01, R34 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this FOA is to support R01-level projects that will address polysubstance use involving opioids and stimulants that can contribute to 1) understanding of the dynamics of polysubstance use, 2) improving outcome measurement in the context of polysubstance use, 3) personalizing preventative and treatment services approaches in the context of polysubstance use. 

This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative bolsters research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://heal.nih.gov/

Applicants who do not have relevant preliminary data are encouraged to apply to RFA-DA-22-048, HEAL Initiative: Pilot & Feasibility Trials to Improve Service Delivery for Polysubstance Use. Applicants who seek to conduct efficacy research or earlier stage translational research are encouraged to apply to PAR-20-035, Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional).  


  • Letter of Intent Due Date(s): Feb. 10, 2022

  • Application: March 10, 2022

RFA-DA-22-047 Expiration Date March 11, 2022

Agency Website



Amount Description

Application budgets are limited to $500,000 in direct costs per year and need to reflect the actual needs of the proposed project.  

The maximum project period is 5 years. 

Funding Type





Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

March 10, 2022